Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer

Hoshi,Senji; Numahata,Kenji; Kanno,Hidenori; Sato,Masahiko; Kuromoto,Akihito; Nezu,Kunihisa; Sakai,Takanari; Konno,Chihito; Ishizuka,Yuichi; Izumi,Hideaki; Taguchi,Katsuyuki; Ono,Kunio; Hoshi,Kiyotsugu; Kanto,Satoshi; Takahashi,Rika; Vladimir,Bilim; Akimoto,Naoe; Sasagawa,Isoji; Ohta,Shoichiro

doi:10.3892/mco.2017.1371

Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer

Authors:
- Senji Hoshi
- Kenji Numahata
- Hidenori Kanno
- Masahiko Sato
- Akihito Kuromoto
- Kunihisa Nezu
- Takanari Sakai
- Chihito Konno
- Yuichi Ishizuka
- Hideaki Izumi
- Katsuyuki Taguchi
- Kunio Ono
- Kiyotsugu Hoshi
- Satoshi Kanto
- Rika Takahashi
- Bilim Vladimir
- Naoe Akimoto
- Isoji Sasagawa
- Shoichiro Ohta
View Affiliations

Affiliations: Department of Urology, Yamagata Prefectural Central Hospital, Yamagata 990-2292, Japan, Department of Urology, Ishinomaki Red Cross Hospital, Ishinomaki, Miyagi 986-8522, Japan, Department Urology, Yamagata Tokushukai Hospital, Yamagata 990-0834, Japan, Department of Rehabilitation, Yamagata Tokushukai Hospital, Yamagata 990-0834, Japan, Department of Urology, Niigata Prefectural Cancer Center Hospital, Niigata 951-8566, Japan, Clinical Pathology, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan
Published online on: August 11, 2017 https://doi.org/10.3892/mco.2017.1371
Pages: 591-594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular-targeted therapy was recommended for the systemic therapy of renal cell cancer (RCC) in the RCC guidelines, but these guidelines do not address the order of administration of the multiple presently available agents. There are several aspects that remain unknown regarding the optimal administration order and combination of molecular‑targeted drugs. Until the optimal treatment sequence is determined by clinical trials, treatment individualization is required for each patient based on patient and disease characteristics. We herein investigate 12 cases of RCC patients who received axitinib. Axitinib was used as the first‑line drug in 4 cases, second‑line in 5 cases, third‑line in 1 case and as a fourth‑line drug in 2 cases. Partial response (PR) was observed in 4 cases (30%) and stable disease in 4 cases (30%) during axitinib treatment, with an overall response rate of 60%. The duration of PR ranged from 6 to 19 months. Based on our cases, axitinib exhibited reasonable therapeutic efficacy as first‑ as well as second‑line treatment. However, more cases are required to draw firm conclusions.

View Figures

View References

1	Naito S, Tatsugami K, Shinohara N, Tomita Y, Mizokami A, Fujisawa M, Hashine K, Nishikido M, Nakagawa M, Tsukamoto T and Akaza H: Final results of a phase II study of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. Jpn J Clin Oncol. 44:122–126. 2014. View Article : Google Scholar : PubMed/NCBI
2	Japanese Urological Association: Guideline on renal cell carcinoma 66–75. 2011 http://www.urol.or.jp/info/guideline/data/07_kidney_cancer_2011.pdfAccessed. March 17–2015.
3	Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Powles T, et al: Guideline on renal cell carcinoma. European Association of Urology. http://uroweb.org/wp-content/uploads/10-Renal-Cell-Carcinoma_LR1.pdfAccessed. March 17–2015.
4	Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, et al: Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 28:1339–1345. 2017. View Article : Google Scholar : PubMed/NCBI
5	Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Pha SY, et al: Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 32:2765–2771. 2014. View Article : Google Scholar : PubMed/NCBI
6	Yoshinaga A and Kamata S: Long survival in a patient with advanced ureteral carcinoma treated with TIN Regimen (Paclitaxel, Ifosfamide, Nedaplatin) and Radiotherapy: A Case Report. Hinyokika Kiyo. 60:435–437. 2014.(In Japanese). PubMed/NCBI
7	Hoshi S, Ohyama C, Ono K, Takeda A, Yamashita S, Yamato T, Itoh A, Satoh M, Saito S, Okada Y, et al: Gemcitabine plus carboplatin; and gemcitabine, docetaxel and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: Preliminary report. Int J Clin Oncol. 9:125–129. 2004. View Article : Google Scholar : PubMed/NCBI
8	Procopio G, Testa I, Iacovelli R, Grassi P, Verzoni E, Garanzini E, Colecchia M, Torelli T and De Braud F: Treatment of collecting duct carcinoma: Current status and future perspectives. Anticancer Res. 34:1027–1030. 2014.PubMed/NCBI
9	Biondani P, Verzoni E, Torri V, Porcu L, Grassi P, Testa I, DE Braud F and Procopio G: Sequential tyrosine kinase inhibitors (TKIs) in metastatic renal cell carcinoma: Results from a large cohort of patients. Anticancer Res. 34:2395–2398. 2015.
10	Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E and Schmidinger M: Axitinib safety in metastatic renal cell carcinoma: Suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf. 13:497–510. 2014. View Article : Google Scholar : PubMed/NCBI
11	Procopio G, Verzoni E, Biondani P, Grassi P, Testa I, Garanzini E and de Braud F: Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. Tumori. 100:e28–e30. 2014.PubMed/NCBI
12	Grüenwald V, Lin X, Kalanovic D and Simantov R: Early tumor shrinkage (eTS) as a predictive and prognostic factor in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 33 (suppl; abstr 4551):2015.
13	Motzer R, Hutson T, Glen H, Michaelson D, Molina AM, Eisen T, Jassem J, Zolnierek J, Maroto P, Mellado B, et al: Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE) and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 33 (suppl; abstr 4506):2015. View Article : Google Scholar : PubMed/NCBI
14	Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, et al: Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 21:1071–1077. 2015. View Article : Google Scholar : PubMed/NCBI
15	Armstrong AJ, Broderick S, Eisen T, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, et al: Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). J Clin Oncol. 33 (suppl; abstr 4507):2015.
16	Thoma C: Kidney cancer: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival. Nat Rev Clin Oncol. 12:6212015. View Article : Google Scholar : PubMed/NCBI
17	Michel Ortega RM and Drabkin HA: Nivolumab in renal cell carcinoma. Expert Opin Biol Ther. 15:1049–1060. 2015. View Article : Google Scholar : PubMed/NCBI
18	Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015. View Article : Google Scholar : PubMed/NCBI
19	Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, et al: Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res May. 11:2016.(Epub ahead of print).
20	Nadal R, Amin A, Geynisman DM, Voss Martin HM, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, et al: Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 33:45662015.
21	Ho TH, Millis SZ, Bryant D, Gatalica Z, Reddy SK, Stanton ML, Castle EP, Joseph RW and Vogelzang NJ: Molecular analysis of sarcomatoid renal cell carcinoma (sRCC). J Clin Oncol. 33 (suppl; abstr 4556):2015. View Article : Google Scholar
22	Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B and Choueiri TK: Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Eur J Cancer. 51:2580–2586. 2015. View Article : Google Scholar : PubMed/NCBI